1. Home
  2. ITCI

ITCI

Intra-Cellular Therapies Inc.

Logo Intra-Cellular Therapies Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-22-2024 4:00pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

Founded: N/A Country:
United States
United States
Employees: N/A City: NEW YORK
Market Cap: 6.3B IPO Year: N/A
Target Price: $88.17 AVG Volume (30 days): 951.2K
Analyst Decision: Strong Buy Number of Analysts: 12
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.46 EPS Growth: N/A
52 Week Low/High: $45.50 - $76.11 Next Earning Date: 05-02-2024
Revenue: $464,370,000 Revenue Growth: 85.51%
Revenue Growth (this year): 45.2% Revenue Growth (next year): 40.33%

Share on Social Networks:

Stock Insider Trading Activity of Intra-Cellular Therapies Inc. (ITCI)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Mates Sharon ITCI Chairman, President & CEO Mar 7 '24 Sell $67.33 306 $20,602.98 1,050,309 SEC Form 4
Mates Sharon ITCI Chairman, President & CEO Mar 7 '24 Sell $66.81 1,590 $106,227.90 1,050,615 SEC Form 4
Mates Sharon ITCI Chairman, President & CEO Mar 7 '24 Sell $65.90 4,128 $272,035.20 1,052,205 SEC Form 4
Mates Sharon ITCI Chairman, President & CEO Mar 7 '24 Sell $64.80 14,541 $942,256.80 1,056,333 SEC Form 4
Mates Sharon ITCI Chairman, President & CEO Mar 7 '24 Sell $66.93 8,754 $585,905.22 1,050,309 SEC Form 4
Mates Sharon ITCI Chairman, President & CEO Mar 7 '24 Sell $66.38 31,958 $2,121,372.04 1,059,063 SEC Form 4
MARCUS JOEL S ITCI Director Feb 26 '24 Sell $69.60 299 $20,810.40 39,662 SEC Form 4
MARCUS JOEL S ITCI Director Feb 26 '24 Sell $69.07 17,658 $1,219,638.06 39,961 SEC Form 4
MARCUS JOEL S ITCI Director Feb 26 '24 Sell $67.83 8,371 $567,804.93 57,619 SEC Form 4
Hineline Lawrence J. ITCI SVP of Finance, CFO Feb 23 '24 Sell $69.81 600 $41,886.00 0 SEC Form 4
Hineline Lawrence J. ITCI SVP of Finance, CFO Feb 23 '24 Sell $69.47 5,282 $366,940.54 600 SEC Form 4
Hineline Lawrence J. ITCI SVP of Finance, CFO Feb 23 '24 Sell $70.15 288 $20,203.20 0 SEC Form 4
Hineline Lawrence J. ITCI SVP of Finance, CFO Feb 23 '24 Sell $69.38 6,867 $476,432.46 288 SEC Form 4
Hineline Lawrence J. ITCI SVP of Finance, CFO Feb 23 '24 Sell $68.33 300 $20,499.00 7,155 SEC Form 4
Neumann Mark ITCI EVP, Chief Commercial Officer Feb 1 '24 Sell $67.49 6,904 $465,950.96 29,700 SEC Form 4
Neumann Mark ITCI EVP, Chief Commercial Officer Feb 1 '24 Sell $66.67 4,956 $330,416.52 36,604 SEC Form 4
Mates Sharon ITCI Chairman, President & CEO Feb 1 '24 Sell $67.42 17,450 $1,176,479.00 1,050,309 SEC Form 4
Mates Sharon ITCI Chairman, President & CEO Feb 1 '24 Sell $66.70 16,435 $1,096,214.50 1,067,759 SEC Form 4
Halstead Michael ITCI EVP and General Counsel Feb 1 '24 Sell $67.17 714 $47,959.38 0 SEC Form 4
Halstead Michael ITCI EVP and General Counsel Feb 1 '24 Sell $66.37 11,146 $739,760.02 714 SEC Form 4
Durgam Suresh K. ITCI EVP, Chief Medical Officer Dec 13 '23 Sell $65.00 21,262 $1,382,030.00 0 SEC Form 4
Halstead Michael ITCI EVP and General Counsel Nov 13 '23 Sell $54.01 41,067 $2,218,028.67 0 SEC Form 4
Halstead Michael ITCI EVP and General Counsel Nov 13 '23 Sell $53.37 8,933 $476,754.21 41,067 SEC Form 4